Biotech · Private company · San Leandro, CA, US
Mercator MedSystems, Inc.
Track this companyFree. Adds Mercator MedSystems, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- TemsirolimusPhase 3 · Peripheral Artery DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mLPhase 2 · Chronic Limb IschemiaClinicalTrials.gov · fetched Nov 12, 2026
- Perivascular dexamethasonePhase 2 · Iliofemoral; ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- Perivascular dexamethasonePhase 2 · Thrombosis, Deep VeinClinicalTrials.gov · fetched Nov 12, 2026
- Perivascular shamPhase 2 · Iliofemoral; ThrombosisClinicalTrials.gov · fetched Nov 12, 2026
- Perivascular shamPhase 2 · Thrombosis, Deep VeinClinicalTrials.gov · fetched Nov 12, 2026
- TemsirolimusPhase 2 · Chronic Limb IschemiaClinicalTrials.gov · fetched Nov 12, 2026
- TemsirolimusPhase 2 · Peripheral Arterial DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Temsirolimus and dexamethasone sodium phosphatePhase 2 · Peripheral Arterial DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the KneePHASE3 · RECRUITING · started Jul 30, 2025ClinicalTrials.gov NCT04433572 · fetched Nov 12, 2026
- Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVTPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 8, 2022ClinicalTrials.gov NCT04858776 · fetched Nov 12, 2026
- Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVTPHASE2 · RECRUITING · started Oct 29, 2021ClinicalTrials.gov NCT04862468 · fetched Nov 12, 2026
- Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal RevascularizationPHASE2 · TERMINATED · started Oct 1, 2019ClinicalTrials.gov NCT03942601 · fetched Nov 12, 2026
- Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)PHASE2 · UNKNOWN · started Mar 3, 2017ClinicalTrials.gov NCT02908035 · fetched Nov 12, 2026
- Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based RevascularizationPHASE2 · UNKNOWN · started Jun 1, 2016ClinicalTrials.gov NCT02479620 · fetched Nov 12, 2026
NIH awards5
- Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery DiseaseFiscal year 2026 · $1MNIH RePORTER 5R44HL102998-06 · fetched Nov 12, 2026
- Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery DiseaseFiscal year 2025 · $1MNIH RePORTER 5R44HL102998-05 · fetched Nov 12, 2026
- Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent DeliveryFiscal year 2025 · $1.1MNIH RePORTER 5R44HL160434-03 · fetched Nov 12, 2026
- Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery DiseaseFiscal year 2024 · $1MNIH RePORTER 2R44HL102998-04 · fetched Nov 12, 2026
- Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent DeliveryFiscal year 2024 · $1.6MNIH RePORTER 2R44HL160434-02 · fetched Nov 12, 2026